MannKind (Nasdaq:MNKD) today announced new clinical findings for its Afrezza inhaled insulin powder and Furoscix furosemide injection. The company shared outcomes at the American Diabetes Association Scientific Sessions (ADA 2026) in New Orleans. MannKind’s Afrezza (insulin human) inhalation powder is a fast-acting insulin formulation delivered through an inhaler device. MannKind engineered the mechanical inhaler device to […]
Pharmaceuticals
MannKind wins FDA approval for inhaled insulin for children with type 1, type 2 diabetes
MannKind (Nasdaq:MNKD) announced today that it received FDA approval for its Afrezza inhaled insulin powder for children. FDA approval covers use in children and adolescents aged 6 and older with type 1 and type 2 diabetes. Afrezza (insulin human) inhalation powder is a fast-acting insulin formulation delivered through an inhaler device. MannKind engineered the mechanical inhaler […]
West Pharmaceutical Services opens expanded Dublin facility for injectable therapies
West Pharmaceutical Services (NYSE:WST) announced the opening of a new facility for contract services in Dublin, Ireland. IDA Ireland, the foreign direct investment arm for the Irish government, shared the announcement of the Damastown site’s opening. The 165,000-square-foot expansion enhances West’s contract services. It helps meet the growing demand for high-volume treatments, including for diabetes […]
BD launches Pyxis medication dispensing tech in Europe
BD (NYSE:BDX) announced today that it launched its Pyxis Pro Dispensing Solution and Incada Connected Care Platform in Europe. The next-generation medication dispensing system combines advanced automation and AI insights to modernize medication management. It helps reduce disruptions and improve efficiency while helping clinicians spend more time on patient care. Franklin Lakes, New Jersey-based BD […]
Novo Nordisk gets FDA nod for Awiqli once-weekly basal insulin for type 2 diabetes
Novo Nordisk announced today that it received FDA approval for Awiqli, the first and only once-weekly, long-acting basal insulin. Awiqli (insulin icodec-abae) injection 700 units/mL, is indicated as an adjunct to diet and exercise to improve glycemic control (blood sugar) in adults living with type 2 diabetes. Approval grants people with type 2 diabetes a […]
Vivani advances development of semaglutide implant
Vivani Medical (Nasdaq:VANI) provided updates this week on its progress and plans related to NPM-139, the company’s semaglutide implant. Alameda, California-based Vivani completed LIBERATE-1, which evaluated its miniature GLP-1 implant in obese and overweight subjects. The company initiated its LIBERATE-1 trial at two centers in Australia at the end of 2024. This study followed FDA […]
Vaxess rebrands to Terrestrial Bio, raises $50M for GLP-1 patch
Vaxess Technologies today announced a rebranding to Terrestrial Bio, Inc., along with $50 million in Series C financing. Boston-based Terrestrial Bio rebranded to reflect its strategic focus on transforming the delivery and accessibility of its therapies. That starts with GLP-1 therapeutics, delivered using the company’s microarray patch (MAP). The technology features a soluble microarray with […]
Thermo Fisher, SHL Medical collab on drug delivery device production
Thermo Fisher Scientific today announced a strategic collaboration with drug delivery system provider SHL Medical. The collaboration coincides with the expansion of sterile fill-finish and auto-injector final assembly capacity at its Ridgefield, New Jersey site. Together, Thermo Fisher says its investments establish a fully integrated U.S.-based offering across sterile manufacturing, device assembly and commercial packaging […]
Embecta to acquire auto-injector maker Owen Mumford for up to $199.4M
Embecta (Nasdaq:EMBC) announced today that it entered into a definitive agreement to acquire Owen Mumford Holdings Limited. Owen Mumford, a privately held, UK-based company, develops and manufactures medical devices and drug delivery technologies. Embecta, the former BD Diabetes business, agreed to acquire Owen Mumford with an upfront cash payment of approximately $133 million (£100 million). […]
MannKind enrolls first patient in study of inhaled insulin for pediatric type 1 diabetes
MannKind (Nasdaq:MNKD) announced today that it enrolled the first patient in the INHALE-1ST study of its Afrezza inhaled insulin. INHALE-1ST evaluates the initiation of Afrezza inhalation powder therapy shortly after type 1 diabetes diagnosis in pediatric patients. Afrezza (insulin human) inhalation powder is a fast-acting insulin formulation delivered through an inhaler device. MannKind engineered the mechanical […]
